Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03892564 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
A Phase 1 study of Phototoxicity, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03892564: Completed Phase 1 study of Phototoxicity, sponsored by MC2 Therapeutics.
NCT03892564 is a Phase 1 study of Phototoxicity that has completed, run by MC2 Therapeutics. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03892564, a Phase 1 study of Phototoxicity, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
Primary Outcome
MC2-01 Cream, MC2-01 vehicle will be applied each to two sites. One further site will function as control site and will remain untreated. 24 hours after product application, the test sites, including the untreated control site will be evaluated for cutaneous reaction. One set of MC2-01 and MC2-01 vehicle + the untreated control site will be designated for irradiation and the other set will remain non-irradiated. Possible changes in dermal reactions (erythema, edema and other signs of cutaneous i
Conditions Studied
Interventions
- DRUG MC2-01 Cream, irradiation
- DRUG MC2-01 Cream, no irradiation
- DRUG MC2-01 vehicle, irradiation
- DRUG MC2-01 vehicle, no irradiation
- DRUG Control, irradiation
Study Locations (1)
New Jersey
- TKL Research Inc - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2019-03-09 |
| Phase | Phase 1 |
What the finished NCT03892564 record still lists
NCT03892564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Phototoxicity appearing as the primary indexed condition, and to 5 interventions - of which MC2-01 Cream, irradiation is the first listed.
NCT03892564 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03892564 about?
NCT03892564 is a clinical study titled "Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream". This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
What is the current status of trial NCT03892564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-02-27. Estimated completion is 2019-03-09.
What conditions does trial NCT03892564 study?
This clinical trial studies the following conditions: Phototoxicity.
What interventions are being tested in trial NCT03892564?
The interventions under investigation include: MC2-01 Cream, irradiation (DRUG), MC2-01 Cream, no irradiation (DRUG), MC2-01 vehicle, irradiation (DRUG), MC2-01 vehicle, no irradiation (DRUG), Control, irradiation (DRUG).
Who is sponsoring clinical trial NCT03892564?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03892564 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03892564's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI